8-Methly-4-(3-diethylaminopropylamino) pyrimido [4′,5′;4,5] thieno (2,3-b) quinoline (MDPTQ), a quinoline derivate that causes ROS-mediated apoptosis in leukemia cell lines

Toxicology and Applied Pharmacology

Volumn 222, Issue 1, 2007, Pages 80-88

  Shenoy, Sudheer ^a   Vasania, Viraf S ^a   Gopal, M ^b   Mehta, Ashish ^a  

^a RELIANCE LIFE SCIENCES PVT LTD   (India)

^b KUVEMPU UNIVERSITY   (India)

Author keywords

Apoptosis; Ellipticine; HL 60; Leukemia; Mitochondrial potential; Quinoline derivate; Reactive oxygen species

Indexed keywords

8 METHYL 4 (3 DIETHYLAMINOPROPYLAMINO)PYRIMIDO[4',5';4,5]THIENO[2,3 B]QUINOLINE; ACETYLCYSTEINE; CASPASE 3; ELLIPTICINE; PHOSPHATIDYLSERINE; QUINOLINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; 8 METHYL 4 (3 DIETHYLAMINOPROPYLAMINO)PYRIMIDO(4',5' 4,5)THIENO(2,3 B) QUINOLINE; 8-METHYL-4-(3-DIETHYLAMINOPROPYLAMINO)PYRIMIDO(4',5'-4,5)THIENO(2,3-B) QUINOLINE; ANTINEOPLASTIC AGENT; ELLIPTICINE DERIVATIVE; LIPOCORTIN 5; THIOPHENE DERIVATIVE;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; BIOSYNTHESIS; CELL CYCLE; CELL MEMBRANE POTENTIAL; DNA DAMAGE; DRUG EFFECT; DRUG SCREENING; FLOW CYTOMETRY; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALIA;

ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; DNA DAMAGE; ELLIPTICINES; FLOW CYTOMETRY; HUMANS; LEUKEMIA; MEMBRANE POTENTIALS; MITOCHONDRIAL MEMBRANES; PHOSPHATIDYLSERINES; QUINOLINES; REACTIVE OXYGEN SPECIES; THIOPHENES; TUMOR STEM CELL ASSAY;

EID: 34250734948     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.04.005     Document Type: Article

References (36)

1. Auclair C. Multimodal action of antitumor agents on DNA: the ellipticine series. Arch. Biochem. Biophys. 259 (1987) 1-14
2. Borek-Dohalska L., Frei E., and Stiborova M. DNA adduct formation by the anticancer drug ellipticine and its hydroxyl derivatives in human adenocarcinoma MCF-7 cells. Collect. Czechoslov. Chem. Commun. 69 (2004) 603-615
3. Broxmeyer H.E., Baker F.L., and Galbraith P.R. Relationship of colony stimulating activity to apparent kill of human colony forming cells by irradiation of hydroxyurea. Blood 47 (1976) 403-410
4. Darzynkiewicz Z., and Li X. In: Cotter T.G., and Martin S.J. (Eds). Techniques in Apoptosis (1999), Portland Press, London 72-106
5. Diomede L., Colotta F., Piovani B., Re F., Modest E.J., and Salomona M. Induction of apoptosis in human leukemic cells by the ether lipid 1-octadecyl-2-methyl-rac-glycero-phocphocholine; a possible basis for its selective action. Int. J. Cancer 53 (1993) 30-124
6. Fossé P., René B., Charra M., Paoletti C., and Saucier J.M. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationships. Mol. Pharmacol. 42 (1992) 590-595
7. Frei E., Bieler C.A., Arlt V.M., Wiessler M., and Stiborová M. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem. Pharmacol. 64 (2002) 289-295
8. Geilin C.C., Haase R., Buchner K., Wirder T., Hucho F., and Reutter W. The phospholipid analogue, hexadecylphosphocholine inhibits protein kinase C in in vitro and antagonises phorbol ester-stimulated cell proliferation. Eur. J. Cancer 27 (1991) 1650-1653
9. Goodwin S., Smith A.F., and Horning E.C. Alkaloids of Ochrosia elliptica Labill. J. Am. Chem. Soc. 81 (1959) 1903-1908
10. Gopal M., Shenoy S., and Doddamani L.S. Antitumor activity of 4-amino and 8-methly-4-(3-diethylaminopropylamino) pyrimido [4′,5′;4,5] thieno (2,3-b) quinolines. J. Photochem. Photobiol., B Biol. 72 (2003) 69-78
11. Heesbeen E.C., Verdonck L.F., Hermans S.W.G., Van-Heutgen, Staal G.H., and Rijksen G. Alkyllysophospholipid ET-18-OCH3 acts as an activator of protein kinase Cin HL-60 cells. FEBS Lett. 290 (1991) 231-234
12. Hoffman D.R., Thomas V.L., and Snyder F. Inhibition of cellular transport systems by alkyl phospholipid analogues in HL-60 human leukemia cells. Biochim. Biophys. Acta 1127 (1992) 74-80
13. Kelso G.F., Porteous C.M., Coulter C.V., Hughes G., Porteous W.K., Ledgerwood E.C., Smith R.A., and Murphy M.P. Selective targeting of a redox-active ubiquinone to mitochondria within cells. Antioxidant and antiapoptotic properties. J. Biol. Chem. 276 (2001) 4588-4596
14. Kelso G.F., Porteous C.M., Hughes G., Porteous W.K., Ledgerwood E.C., Gane A.M., Smith R.A., and Murphy M.P. Prevention of mitochondrial oxidative damage using targeted antioxidants. Ann. N. Y. Acad. Sci. 959 (2002) 263-274
15. Kuo P.L., Hsu Y., Chang C., and Lin C. The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett. 223 (2005) 293-301
16. Lemasters J.J., Qian T., Bradham C.A., Brenner D.A., Cascio W.A., Trost L.C., Nishimura Y., Nieminen A.L., and Herman B. Mitochondrial dysfunction in the pathogenesis of necrotic and apoptotic cell death. J. Bioenerg. Biomembranes 31 (1999) 305-319
17. Margert C.M.V., Juliet M.P., and Mark B.H. Hypochlorous acid causes caspase activation and apoptosis or growth arrest in human endothelial cells. Biochem. J. 344 (1999) 443-449
18. Mathe G., Triana K., Pontiggia P., Blanquet D., Hallard M., and Morette C. Data of pre-clinical and early clinical trials of acriflavine and hydroxy-methyl-ellipticine reviewed, enriched by the experience of their use for 18 months to 6 years in combination with other HIV1 virostatic. Biomed. Pharmacother. 52 (1998) 391-396
19. Mehta A., and Shaha C. Apoptotic death in Leishmania donovani promastigotes in response to respiratory chain inhibition: complex II inhibition results in increased pentamidine cytotoxicity. J. Biol. Chem. 279 (2004) 11798-11813
20. 2+, and glutathione. Free Radic. Biol. Med. 40 (2006) 1857-1868
21. Moinet-Hedis V., Tabaka T., Poulain L., Godard T., Lechevrel M., Saturnino C., Lancelot J.C., Le J.Y., and Gaudunchon P. Biological properties of 5,11-dimethyl-6H-pyrido (3,2-b) carbazoles: a new class of potent antitumor drugs. Anticancer Drug Des. 15 (2000) 109-118
22. Mollinedo F., Fernandez-Luna J.L., Gajate C., Martin-Martin B., Bentio A., Martinez-Dalmau R., and Modolell M. Selective induction of apoptosis in cancer cells bythe ether lipid-ET-18-OCH3 (Edelfosine); molecular structure requirements, cellular uptake and protection by BCl-2 and BCl-XL. Cancer Res. 57 (1997) 1320-1328
23. Pelicano H., Feng L., Zhou Y., Carew J.S., Hileman S., Plunkett W., Keating M.J., and Huang P. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem. 278 (2003) 37832-37839
24. Poljakova J., Forsterova K., Šulc M., Frei E., and Stiborova M. Oxidation of ellipticine by peroxidases. Biomed. Papers 149 (2005) 449-453
25. Ritke M.K., Rusnak J.M., Lazo J.S., Allan W.P., Dive C., Heer S., and Yalowich C. Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K-562 cells. Mol. Pharmacol. 46 (1994) 605-611
26. Sandeu K., Pfeilschifter J., and Brune B. Nitric oxide and superoxide induced p53 and Bax accumulation during mesangial cell apoptosis. Kidney Int. 52 (1997) 378-386
27. Shoieb A.M., Elgayyar M., Oudrick P.S., Bell J.L., and Tithof P.K. In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. Int. J. Oncol. 22 (2003) 107-113
28. Singh M.P., Hill G.C., Peoch D., Rayner B., Inabach J.L., and Lown J.W. High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry 33 (1994) 10271-10285
29. Stiborová M., Stiborová-Rupertová M., Bořek-Dohalská L., Wiessler M., and Frei E. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem. Res. Toxicol. 16 (2003) 38-47
30. Stiborová M., Breuer A., Aimová D., Stiborová-Rupertová M., Wiessler M., and Frei E. DNA adduct formation by the anticancer drug ellipticine in rats determined by32P-postlabeling. Int. J. Cancer 107 (2003) 885-890
31. Stiborova M., Rupertova M., Schmeiser H.H., and Frei E. Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech. Repub. 150 1 (2006) 13-23
32. Takeuchi Y., Oda T., Chang M.R., Okamoto Y., Ono J., Oda Y., Harada K., Hashigaki K., and Yamoto M. Synthesis and antitumor activity of fused quinoline derivatives. IV. Novel 11-aminoindolo (2,3-b)quinolines. Chem. Pharm. Bull. Tokyo 45 (1997) 406-411
33. Pi{dotless}:4,5] thieno (2,3-b) quinoline-4(3H)-ones. J. Chem. Res. 50 (1988) 537-551
34. Traganos F., Kapuscinski J., and Darzynkiewicz Z. Caffeine modulates the effects of DNA intercalating drugs, in vitro: a flowcytometric and spectrophotometric analysis of caffeine interaction with novantrone, doxorubicin, ellipticine and doxorubicin analogue AD198. Cancer Res. 51 (1991) 3682-3689
35. Vermes I., Haonen C., Steffens N.H., and Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cell using fluorescein labelled annexin V. J. Immunol. Methods 184 (1995) 39-51
36. Williams J.A., and Phillips D.H. Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. Cancer Res. 60 (2000) 4667-4677